Pregabalin: A new neuromodulator with broad therapeutic indications

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2029-2037

  Shneker, Bassel F ^a   McAuley, James W ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Diabetic neuropathy; Epilepsy; Neuropathic pain; Postherpetic neuralgia; Pregabalin: Anxiety; Seizures

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL;

ADULT; AMBLYOPIA; AMNESIA; ANXIETY; ASTHENIA; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIARRHEA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HEADACHE; HEMIPARESIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NERVOUSNESS; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTOXICITY; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT INDICATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

AGORAPHOBIA; ANXIETY; DIABETIC NEUROPATHIES; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HERPESVIRIDAE INFECTIONS; HUMANS; MULTICENTER STUDIES; NEURALGIA; NEUROTRANSMITTER AGENTS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS; SEIZURES;

EID: 28544434497     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G078     Document Type: Review

References (63)

1. FDA approval letter of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy. Department of Health & Human Services. www.fda.gov/cder/foi/appletter/2004/214461tr.pdf (accessed 2005 Aug 16).
2. FDA approval letter of pregabalin for the management of postherpetic neuralgia. Department of Health & Human Services. www.fda.gov/cder/foi/ appletter/2004/217231tr.pdf (accessed 2005 Aug 16).
3. FDA approval letter of pregabalin as adjunctive therapy for adult patients with partial onset seizures. Department of Health & Human Services. www.fda.gov/cder/foi/appletter/2005/0217241tr.pdf (accessed 2005 Aug 16).
4. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Register 2005;70:43633-5.
5. 2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry 2004;65:1033-4.
6. Taylor CP. The biology and pharmacology of calcium channel alpha 2-delta proteins. CNS Drug Rev 2004;10:159-64.
7. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-41.
8. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(suppl 6):13-8.
9. Corrigan BW, Pool WF, Posvar EL, Strand JC, Alvey CW, Radulovic LL, et al. Metabolic disposition of pregabalin in healthy volunteers (abstract). Clin Pharmacol Ther 2001;69:P18.
10. Bockbrader HN, Hunt T, Strand J, Posvar E, Sedman A. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies (abstract). Neurology 2000;54(suppl 3):A421.
11. Busch JA, Strand JC, Posvar EL, Bockbrader HN, Radulovic LL. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses (abstract). Epilepsia 1998;39(suppl 6):58.
12. Corrigan B, Burger P, Bockbrader H. Population pharmacokinetics of pregabalin in healthy volunteers, renally impaired patients and patients with chronic pain (abstract). J Pain 2002;3(suppl 1):47.
13. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43:277-83.
14. Elwes RD, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996;30:403-15.
15. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epil Res 2004;61:1-48.
16. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-7.
17. Dworkin RH, Corbin AE, Young JP Jr, Ahrma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
18. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63.
19. Sabatowski R, Galvez R, Cherry DA, Florence J, Vincent E, Maisonobe P, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35.
20. Van Seventer R, Bladin C, Hoggart B, Martin S, Ziekenhuis B. Pregabalin dosed twice a day (BID) efficaciously and safely treats neuropathic pain associated with postherpetic neuralgia (abstract). Anesthesiology 2004;101:A1135.
21. Lesser H, Sharma U, Lamoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;62:2104-10.
22. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38.
23. Richter R, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp L. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60.
24. Toelle T, Versavel M, Glessner C, Trostman U. A novel treatment for diabetic peripheral neuropathy: pregabalin dose and pain relief (abstract). Anesthesiology 2004;101:A967.
25. Melzak R. The short-form McGill pain questionnaire. Pain 1987;30:191-7.
26. Hayes RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring functioning and well-being. Durham, NC: Duke University Press, 1992:235-59.
27. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, 1976.
28. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
29. McNair DM, Lorr M, Droppleman LF. Profile of mood states manual. San Diego: Educational and Industrial Testing service, 1971.
30. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
31. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN, Gershon AA, eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press, 2001:39-64.
32. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia. Neurology 2004;63:959-65.
33. Rowbotham M, Young JR, Sharma U, Knapp K. Pregabalin shows reduction in pain by day 3 of treatment (abstract). Eur J Neurol 2003;10 (suppl 1):73.
34. Arroyo S, Anhut H, Kugler A, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-7.
35. Beydoun AA, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64:475-86.
36. Guberman A, Anhut H, Lee C, Hsu T. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible and fixed dosing (abstract). Neurology 2004;62(suppl 5):A313.
37. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004;45(suppl 6):19-27.
38. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
39. Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 2004;65(suppl 13):8-13.
40. Dupont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety 1996;2:167-72.
41. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double blinded, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9.
42. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
43. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005;25:151-8.
44. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30.
45. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232-41.
46. Lipman L, Covi R. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer RL, Klein DL, eds. Evaluation of the psychological therapies. Baltimore: Johns Hopkins University Press, 1976:181-202.
47. Raskin A, Schulterbrandt J, Reating N, McKeon JJ. Replication of factors of psychopathology in interview, ward behavior and self-report rating of hospitalized depressives. J Nerv Ment Dis 1969;148:87-98.
48. Hamilton M. The assessment of anxiety status by rating. Br J Med Psychol 1959;32:50-5.
49. Wittchen HU, Fehm L. Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. Psychiatr Clin North Am 2001;24:617-41.
50. Davidson JRT. Pharmacotherapy of social phobia. Acta Psychiatr Scand 2003;108(suppl 417):65-71.
51. Pande AC, Feltner DE, Jefferson JW, Davidson RT, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-9.
52. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-13.
53. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73.
54. Hamilton M. A rating scale of depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
55. Morrell M, Brigell M, Chartier K, Barrett JA. A double-blind, placebo-controlled, parallel-group study to assess the effects of pregabalin on reproductive function in healthy males (abstract). Neurology 2004;62(suppl 5):A96.
56. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005;5:1-11.
57. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001;42:790-2.
58. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long term therapeutic use of benzodiazepines, I: effect of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907.
59. Bockbrader HN, Burger PJ, Kugler AR, Knapp LE, Garofalo EA, Lalonde RL. Population pharmacokinetic analyses of commonly prescribed antiepileptic drugs coadministered with pregabalin in adult patients with refractory partial seizures (abstract). Epilepsia 2001;42(suppl 7):84.
60. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazapine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13.
61. Bockbrader HN, Psovar EL, Hunt T, Randinitis EJ. Pregabalin does not alter the effectiveness of an oral contraceptive (abstract). Neurology 2004;62(suppl 5):A97.
62. Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo EA, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther 2003;73:491-505.
63. Master Drug Data Base-Select. www.rxsolutions.com/c/rxnews/rxnews_ view.asp?Article=602&type=18 (accessed 2005 Oct 18).